SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Neuland Laboratories reports Profit after tax of Rs 72.47 Mln, in the September 2020 quarter

03 Nov 2020 Evaluate
The sales figure stood at Rs. 2413.93 millions for the September 2020 quarter. The mentioned figure indicates a growth of about 29.63% as compared to Rs. 1862.18 millions during the year-ago period.Handsome Net Profit growth of 92.43% reported above the corresponding previous quarter figure of Rs. 72.47 millions to Rs. 37.66 millions.Operating profit for the quarter ended September 2020 rose to 413.66 millions as compared to 254.04 millions of corresponding quarter ended September 2019.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202009 201909 % Var 202009 201909 % Var 202003 201903 % Var
Sales 2413.93 1862.18 29.63 4468.17 3672.25 21.67 7627.11 6668.30 14.38
Other Income 6.06 5.70 6.32 13.03 10.88 19.76 38.86 34.92 11.28
PBIDT 413.66 254.04 62.83 757.99 444.89 70.38 1053.44 613.57 71.69
Interest 35.12 47.83 -26.57 88.81 88.11 0.79 215.71 156.63 37.72
PBDT 378.54 206.21 83.57 669.18 356.78 87.56 837.73 456.94 83.33
Depreciation 92.69 82.81 11.93 181.30 158.34 14.50 312.76 258.60 20.94
PBT 285.85 123.40 131.65 487.88 198.44 145.86 524.97 198.34 164.68
TAX 213.38 85.74 148.87 264.85 104.65 153.08 366.16 36.92 891.77
Deferred Tax 37.66 4.74 694.51 89.13 3.88 2197.16 366.16 -17.52 -2189.95
PAT 72.47 37.66 92.43 223.03 93.79 137.80 158.81 161.42 -1.62
Equity 129.01 129.01 0.00 129.01 129.01 0.00 129.01 129.01 0.00
PBIDTM(%) 17.14 13.64 25.61 16.96 12.11 40.03 13.81 9.20 50.11

Neuland Laboratories Share Price

14998.70 346.20 (2.36%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×